Itraconazole Injection/oral Solution Therapy for Central Nervous System Fungal Infection: an Open Clinical Study
ZHU Li-ping,WENG Xin-hua,YANG Fei-fei,ZHANG Qiang-qiang,LI Qian,JIN Jia-lin,JIANG Wei-min,SHI Guang-feng,ZHANG Wan-qin,ZHANG Yong-xin
DOI: https://doi.org/10.3969/j.issn.1007-7669.2006.11.006
2006-01-01
Abstract:AIM: To evaluate the efficacy of itraconazole injection and oral solution for the treatment of central nervous system ( CNS) fungal infection, and its safety in combination with amphotericin B, and/or flucytosine. METHODS: Seventeen patients admitted to our hospital with CNS fungal infection were enrolled in an open-label clinical trial from June 2004 to September 2005. They were treated with itraconazole alone or combined with amphotericine B, and/or flucytosine. In this study, patients were treated with itraconazole injection (d 1 - 2, 200 mg, q 12 h; d 3 - 14, 200 mg·d-1) for a minimum of 7 d were included in the efficacy eval- After treated with intraconazole injection, the patients were followed by administration of intraconazole oral solution, and/or in combination with amphotericine B slow intravenouse infusion or flucytosine taken orally. RESULTS: A total of 17 patients included definite (n = 14) or probable (n = 3) CNS fungal infection were enrolled. The identified fungi were Cryptococcus neoformans, Aspergillus spp., and Prototheca wickerhamii. All the patients had headache, fever, and higher than 300 mmH2O intracranial pressure, including 7 patients with underlying diseases, 7 patients with complication of coma and 10 patients with cerebral herniation. Six patients underwent Ommaya-reservoir and ventricular shunt operations. Overall, two patients died at 2 d after the therapy excluding from the efficacy evaluation. The rest 15 patients included 11 (11/15, 73%) with excellent response to this remedy consisting of one with cerebral aspergilloma, one with aspergillus meningitis, one with prototheca wickerhamii meningitis, two with cerebral cryptococcoma, and six with cryptococcal meningitis, only three of them were treated with itraconazole alone. Three patients with cryptococcal meningitis showed partial response and one failed. All patients tolerated well with itraconazole. The adverse reactions including only 2 of mild liver function disorder probably due to intravenous administration and 3 of mild to moderate nausea, loss of appetite after oral intake more than 2 mo. CONCLUSION: Itraconazole injection and oral solution show impressive curing activity on CNS fungal infection together with safety on either itraconazole alone or combined with other antifungal drugs (amphotericine B, and/or flucytosine) .